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Abstract
Introduction: Serum microRNAs have the potential to be valuable biomarkers of cancer. This investigation
addresses two issues that impact their utility: a) appropriate normalization controls and b) whether their altered
levels persist in patients who are clinically free of the disease.
Methods: Sera from 40 age-matched healthy women and 39 breast cancer patients without clinical disease at the
time of serum collection were analyzed for microRNAs let-7f, miR-16, miR-21 and miR-155 using quantitative real-
time PCR. U6 and 5S, which are transcribed by RNA polymerase III (RNAP-III) and the small nucleolar RNU44
(SNORD44), were also analyzed for normalization. Significant results from the initial study were verified using a
second set of sera from 15 healthy patients, 15 breast cancer patients without clinical disease and 15 with
metastatic disease, and a third set of 12 healthy and 18 patients with metastatic disease. U6 was further verified in
the extended second cohort of 75 healthy and 68 breast cancer patients without clinical disease.
Results: U6:SNORD44 ratio was consistently higher in breast cancer patients with or without active disease (fold
change range 1.5-6.6, p value range 0.0003 to 0.05). This increase in U6:SNORD44 ratio was observed in the sera of
both estrogen receptor-positive (ER+) and ER-negative breast cancer patients. MiR-16 and 5S, which are often used
as normalization controls for microRNAs, showed remarkable experimental variability and thus are not ideal for
normalization.
Conclusions: Elevated serum U6 levels in breast cancer patients irrespective of disease activity at the time of
serum collection suggest a new paradigm in cancer; persistent systemic changes during cancer progression, which
result in elevated activity of RNAP-III and/or the stability/release pathways of U6 in non-cancer tissues. Additionally,
these results highlight the need for developing standards for normalization between samples in microRNA-related
studies for healthy versus cancer and for inter-laboratory reproducibility. Our studies rule out the utility of miR-16,
U6 and 5S RNAs for this purpose.
Introduction
MicroRNAs (miRNAs) are a class of multifunctional,
small (18 to 25 nucleotides) non-coding RNA molecules
[1,2]. To date, approximately 940 miRNAs have been
described [3]. Their functions include epigenetic control
of gene expression, mRNA degradation, and suppression
of mRNA translation [4]. These diverse functions of
miRNAs are necessary for normal development, metabo-
lism, cellular differentiation, proliferation, cell cycle con-
trol, and cell death. Aberrant miRNA expression or
activity or both have been implicated in a variety of
human diseases, including cancer [5].
Several studies have analyzed miRNA expression pat-
terns in primary tumors of various types, and specific
subtypes of cancers could be easily differentiated on the
basis of the expression pattern of these miRNAs [6].
Recent studies have identified miRNAs in extracellular
space, mainly through ceramide-dependent secretory
exosomes or microvesicles [7-9]. Additionally, secreted
miRNAs have been shown to be in the Argonaute2 pro-
tein complex, which confers stability [10]. These
secreted miRNAs are transported through high-density
lipoprotein (HDL) and enter heterotypic cells to alter
migration/invasive properties [7,8,11-13]. However,
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a selective process as the level of miRNA in exosomes
secreted by a cell type does not always correlate with
the intracellular levels of the corresponding miRNA
[14]. Specific cellular proteins, most of which are RNA-
binding proteins, are suggested to be involved in exoso-
mal secretion of miRNAs and their stability in circula-
tion [15].
Several reports describe differential blood/plasma/
serum miRNA levels between healthy people and those
with various diseases, including cancer [7-9,14,16-25].
Serum miRNA was first reported in diffuse large B-cell
lymphoma; sera of patients contained higher levels of
miR-155, miR-210, and miR-21 [25]. Elevated serum
miR-21 levels correlated with good prognosis. Similar
studies in prostate cancer revealed elevated levels of
miR-141 in the plasma of patients with cancer compared
with healthy subjects [24], although the same result was
not obtained in another study [23]. A four-miRNA pre-
dictive profile from serum was described recently for
non-small-cell lung cancer [22]. There are limited stu-
dies on breast cancer. One study reported higher serum
levels of miR-155 in patients with progesterone recep-
tor-positive (PR
+) breast cancer compared with patients
with PR
- breast cancer [26]. Two recent studies reported
elevated levels of miR-195 and let-7a in the whole blood
of patients with breast cancer; levels of these miRNAs
declined after surgical removal of tumors, suggesting
that they were tumor-derived [20,21]. Elevated levels of
miR-195 in the whole blood appear to be unique to
breast cancer [21]. Elevated levels of plasma miR-122
and miR-192 were reported after acetaminophen-
induced liver injury, suggesting that tissues that are
enriched for specific miRNAs may release them upon
injury [27]. Patients with atherosclerosis display an
HDL-associated miRNA profile that is distinct from that
of healthy subjects [11].
It is postulated that the miRNAs are released into cir-
culation either actively by the tumor cells or passively as
a result of tumor cell death and lysis [28]. However, this
does not explain low serum levels of some miRNAs in
patients with cancer compared with healthy controls. For
example, plasma of patients with acute myeloid leukemia
shows low levels of miR-92a compared with healthy sub-
jects despite high levels of this miRNA in leukemic cells
[19]. In the sera of patients with lung cancer, 28 miRNAs
are missing and 63 new miRNA species are detectable
compared with healthy subjects [18]. Similarly, sera of
patients with ovarian cancer show elevated levels of five
miRNAs and decreased levels of three miRNAs compared
with healthy subjects [17]. These observations raise ques-
tions of whether serum miRNAs in patients with cancer
are directly derived from tumor cells or an indirect con-
sequence of effects of cancer on other tissues, which then
release miRNA into circulation. Given that the tumor
often represents a very tiny portion of the body mass,
microvesicles/exosomes secreted from the tumor cells
are less likely to be sufficient enough to change the
miRNA profile in a large volume of blood (5 L in a 72-kg
person). Systemic effects of cancer on distant organs
could easily result in a differential serum miRNA profile
in patients with cancer. More importantly, these changes
in serum profile could persist even after the patient is
‘disease-free’ if an epigenetic mechanism is involved in
the systemic effects. In the latter situation, miRNAs
would be poor markers of active disease.
To address these issues, we determined the levels of
breast cancer-associated miRNAs in the sera of healthy
subjects and breast cancer patients who were consid-
ered clinically cancer-free at the time of serum collec-
tion. Further validation of significant initial results was
performed (a) with an independent sample set com-
prising serum from healthy subjects, clinically disease-
free patients with breast cancer, and patients with
o v e r tm e t a s t a s i sa n d( b )w i t has e tw i t hs e r u mf r o m
healthy subjects and patients with active metastasis.
We report that SNORD44, a small nucleolar RNA
(also called RNU44), is similar in the sera of healthy
subjects and clinically cancer-free patients with breast
cancer. However, levels of U6 (also called RNU6-1),
which is commonly used for the purpose of normaliza-
tion between samples, and U6/SNORD44 ratio were
elevated in the sera of breast cancer patients who did
not have active disease. Elevated U6 was detected in
the sera of patients with estrogen receptor alpha-posi-
tive (ERa
+)a n do ft h o s ew i t hE R
- breast cancer. Sera
of patients with overt metastasis also showed elevated
U6 or U6/SNORD44 ratio when compared with
healthy women. Taken together, these results suggest
that elevated U6 serum levels represent persistent sys-
temic effects of breast cancer attained during cancer
progression.
Materials and methods
Sample processing and RNA extraction
All sera were obtained from Indiana University Simon
Cancer Center’s Komen Tissue Bank. Patients gave
informed consent to participate in the study, and the
Indiana University institutional review board that evalu-
ates studies involving human subjects approved the
study. All samples were collected in accordance with
standard operating procedure, which is detailed in the
tissue bank website [29]. More information on serum
collection is provided as Additional file 1. RNA was iso-
lated from 250 μL of serum by using the mirVana kit
(Ambion, part of Applied Biosystems, Foster City, CA,
USA) in accordance with the protocol of the manufac-
turer. RNA was eluted with 70 μL of RNase-free water,
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DE, USA) was used to measure the concentration of
RNA. Although it was reported previously that serum
miRNAs are stable and can withstand repeated freeze-
thawing [24], consistent results were obtained only
when samples from healthy subjects and patients with
cancer were handled similarly.
Quantitative reverse transcription-polymerase chain
reaction
In the first series of experiments, 5 μLo fR N Aw a s
reverse-transcribed to cDNA in a final volume of 15 μL
by using a Taqman miRNA reverse transcription kit
(Applied Biosystems). In the additional cohorts, 25 ng of
RNA was used for reverse transcription. Quantitative
polymerase chain reaction (qPCR) was performed by
using Taqman universal PCR mix (Applied Biosystems)
and specific primers on the qPCR instrument (Applied
Biosystems). Primers for U6 (catalog number 001973),
miR-16 (#000391), miR-21 (#000397), miR-155
(#000479), and miR-195 (#000494) were purchased from
Applied Biosystems, whereas 5S primer (#201509) was
purchased from Exiqon (Vedbaek, Denmark). SNORD44
primers (MPH01658A-200) were purchased from
SABiosciences (Frederick, MD, USA). In some experi-
ments, SNORD44 primers from Applied Biosystems
(also called RNU44, #001094) were used. Each amplifi-
cation reaction was performed in duplicate in a final
volume of 20 μL containing 2 μL of the cDNA. qPCR of
sera from healthy subjects and patients with cancer for
a particular probe was in the same plate in all but
extended cohort 2 to limit mechanical errors. The
expression levels of miRNAs, U6, and 5S were normal-
ized to SNORD44 or miR-16 and were calculated using
the 2
-ΔΔCt method.
Statistical analysis
Expression levels of serum miRNAs were compared by
using the Mann-Whitney U test. A P value of less than
0.05 was considered statistically significant.
Results
Patient characteristics
Table 1 provides details of patient characteristics,
including age at cancer diagnosis, age at serum collec-
tion, tumor types, ER/PR status, treatments received,
and lymph node positivity of the experimental set
(cohort 1). Age range of healthy volunteers (all women)
is also shown. All patients except one were clinically
free of overt metastasis at the time of serum collection.
Patient characteristics of two other validation cohorts
are presented in Tables 2 and 3.
miRNA and small RNA expression analyses
Earlier studies showing the presence of miR-21 and
miR-155 in the serum/plasma of patients with cancer
[25,26] prompted us to evaluate their levels in the sera
of healthy subjects and patients with breast cancer. U6,
5S, miR-16, RNU66, RNU49, RNU19, and SNORD44
levels were also analyzed in these samples to identify a
small RNA expressed at a similar level in equal volume
of sera from both healthy subjects and patients with
cancer to serve as a normalization control. Among
these, miR-16 has previously been used as a normaliza-
tion control for serum miRNA profiling studies [25].
RNU66, RNU48, and RNU19 were undetectable. miR-16
is one of the most abundant miRNAs in the serum
(average cycle threshold (CT) of 24) compared with any
other RNA analyzed, and the abundance of this miRNA
in the serum was similar between healthy subjects and
patients with cancer (Table 4 and Figure 1a). Although
Table 1 Characteristics of healthy volunteers and patients (experimental cohort)
Healthy subjects All patients ER/PR
+ ER/PR
-
Number 40 39 24 12 3
a
Age, years
b Diagnosis Analysis Diagnosis Analysis Diagnosis Analysis
Mean 44 49.9 45.5 51.1 40.9 46.2
Median 20-70 43 50 46 53 40 45
Range 28-64 30-67 28-64 30-67 28-56 36-63
Node-positive/
Node-negative
N/A 14/23 8/16 5/7
Tumor type N/A
Pre-invasive 9 5 2
Invasive 28 17 10
Treatment
Radiation 24 13 8
Chemotherapy 28 16 10
Hormone 23 19 2
aEstrogen receptor/progesterone receptor (ER/PR) status of remaining three patients is unknown.
bAges at the time of initial diagnosis and at the time of serum
collection for analysis are indicated. Patients in this cohort were clinically disease-free at the time of serum collection. N/A, not available.
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(average CT of 32), its levels were similar in the serum
of healthy subjects and patients with breast cancer
(Table 4 and Figure 1b). Unlike in diffuse B-cell lym-
phoma [25], miR-21 did not show any differences
between the two groups, although it is an abundant
miRNA (average CT of 27) (Table 4 and Figure 1c). Let-
7f and miR-155 were not considered for further ana-
lyses, because of higher CT values (> 30). The levels of
U6 and 5S, in contrast to those of the above RNAs,
were higher in the serum of patients with cancer com-
pared with healthy subjects (Table 4 and Figure 1d, e).
These results provided us the first indication of differen-
tial levels of circulating U6 and 5S in patients with
cancer.
Since miR-16 and SNORD44 levels were similar
between two groups, we determined whether the differ-
ences in U6 and 5S levels between healthy subjects and
patients with cancer retain statistical significance if miR-
16 and SNORD44 are used as normalization controls.
Indeed, the levels of U6 and 5S were significantly higher
in the sera of patients with cancer compared with
healthy subjects when miR-16 was used for normaliza-
tion (Table 4 and Figure 2a-d). Differences in U6 levels
remained significant when SNORD44 was used for nor-
malization; however, differences in the levels of 5S did
not reach significance under similar analysis (P =0 . 0 6 )
(Table 4).
Serum U6 and 5S in relation to ER/PR and nodal status of
primary tumors
We next determined whether the upregulation of U6
and 5S observed above is unique to specific subtypes of
breast cancer. ER/PR status of 36 tumors, out of 39
patient samples used in the study, was known; 24 and
12 were ER/PR
+ and ER/PR
-, respectively. In this
Table 2 Characteristics of healthy volunteers and patients with breast cancer during diagnosis and experimental
analysis (cohort 2)
Healthy subjects All patients Non-metastatic Metastatic
Number 15 29 1
a 15 14 1
a
Age, years
b Diagnosis Analysis Diagnosis Analysis Diagnosis Analysis
Mean 53.26 46 52.06 48.06 52.13 43.78 52
Median 53 45 51 48 51 42 53
Range 47-69 23-75 23-80 38-71 46-76 23-75 23-80
Treatment
Radiation 18 8 10
Chemotherapy 19 9 10
Hormone 13 6 7
Only ER
+/PR
+ patients Total Non-metastatic Metastatic
Number 23 13 10
Age, years Diagnosis Analysis Diagnosis Analysis Diagnosis Analysis
Mean 46.34 52.08 48.69 52.38 43.3 51.7
Median 47 51.0 48 51 42 51
Range 23-75 23-80 38-71 46-76 23-75 23-80
aAge and metastatic status of patient are unknown.
bAges at the time of initial diagnosis and at the time of serum collection for analysis are indicated. ER,
estrogen receptor; PR, progesterone receptor.
Table 3 Ages at cancer diagnosis and sample collection of patients with active disease (cohort 3)
All patients with metastasis Bone metastasis Lung/Liver metastasis
Number 18 8 7
Age, years Diagnosis Analysis Diagnosis Analysis Diagnosis Analysis
Mean 43.7 54.9 42.0 54.3 45.2 55.5
Median 43 57.0 42 54.5 43 57
Range 35-58 35-78 35-49 35-78 35-58 45-62
Treatment
Radiation 11 5 6
Chemotherapy 9 4 5
Hormone 8 3 5
Metastasis in three patients was in distant organs other than lung, liver, and bone. Eleven patients had estrogen receptor-positive/progesterone receptor-positive
tumors. Metastasis was more common in bone, lung, and liver.
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the sera of patients with ER/PR
+ breast cancer com-
pared with healthy subjects with or without normaliza-
tion with miR-16 and SNORD44 (Table 5 and Figure 3).
Despite a small sample size, sera of patients with ER/
PR
- demonstrated elevated U6 and 5S levels compared
with healthy subjects when miR-16 or SNORD44 was
used as an internal control (Table 5 and Figure 3). miR-
21 level was similar between healthy subjects and
patients with cancer of either subtype. Note that the dif-
ferences in the levels of these RNAs between ER/PR
+
and ER/PR
- were not statistically significant (data not
shown).
Previous studies have shown that patients with lymph
node-positive breast cancer have lower blood let-7a
levels compared with patients with lymph node-negative
breast cancer, suggesting the influence of metastasis in
regulating serum miRNA levels [20]. In our study, com-
parison of U6 and 5S RNA between sera of node-posi-
tive (n = 14) and node-negative (n = 23) patients did
not reveal any significant difference (data not shown).
These results suggest that the elevated U6 level observed
in the sera of cancer patients who were free of overt
metastasis is less likely to be due to undetectable
micrometastasis.
U6 levels are elevated in sera of patients with breast
cancer, irrespective of metastasis
We collected sera from 15 healthy subjects, 15 clinically
disease-free patients with breast cancer, and 15 patients
with stage IV metastatic disease. RNA from the three
groups (cohort 2) was prepared at the same time from
an equal volume of sera. The cDNA was prepared with
25 ng of RNA and analyzed for the levels of U6, 5S,
miR-21, and miR-16. In this cohort, as with the first
cohort, U6 level was significantly elevated in the sera of
clinically disease-free patients with breast cancer without
normalization (Table 6 and Figure 4) (5.35-fold, P = 3.09
×1 0
-5) or with normalization with SNORD44 (6.6-fold,
P = 0.00028). In this experiment, unlike in the previous
experiments, we found a statistically significant increase
in miR-16 levels in the sera of disease-free patients with
breast cancer compared with healthy subjects with or
without normalization with SNORD44 (Figure 4). These
results suggest that miR-16 is not appropriate for nor-
malization. When the analysis was restricted to patients
with metastasis versus healthy subjects, differences in
U6 levels remained significant without normalization
(Table 6 and Figure 4) (4.31-fold, P = 0.0005) and after
normalization with SNORD44 (4.8-fold, P = 0.004).
Table 4 Differences in the levels of U6, 5S, and other
RNAs between healthy subjects and patients with cancer
Small RNA P value Fold change (cancer/healthy)
U6 0.001 2.42
5S 0.017 1.7
miR-21 0.72 -1.04
miR-16 0.72 -1.06
SNORD44 0.147 1.08
U6-miR-16 0.0047 2.58
U6-SNORD44 0.0028 2.22
5S-miR-16 0.02 1.82
5S-SNORD44 0.0599 1.53
miR-21-miR-16 0.93 1.01
miR-21-SNORD44 0.36 -1.14
In this experimental cohort, patients were cancer-free at the time of serum
collection. miR-16, microRNA 16; miR-21, microRNA 21; SNORD44, small
nucleolar RNA 44.
Figure 1 Levels of miRNAs and small RNAs in sera of healthy
volunteers and patients with breast cancer. (a) MicroRNA 16
(miR-16) levels in the sera of healthy volunteers and patients with
breast cancer. (b) Small nucleolar RNA 44 (SNORD44) levels in the
sera of healthy volunteers and patients with breast cancer. (c) MiR-
21 levels in the sera of healthy volunteers and patients with breast
cancer. (d) U6 small RNA levels in the sera of healthy volunteers
and patients with breast cancer. (e) 5S small RNA levels in the sera
of healthy volunteers and patients with breast cancer. Average cycle
threshold (CT) values are shown; the lower the CT value, higher the
expression. Patients in this cohort were clinically disease-free at the
time of serum collection.
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ease-free patients with breast cancer and patients with
metastasis were not significant. Additionally, SNORD44
levels were similar in all three groups (Table 6 and Fig-
ure 4).
T h em a j o r i t yo fp a t i e n t si nt h i sc o h o r th a dE R / P R
+
breast cancer. We reanalyzed the above data by consid-
ering only ER
+/PR
+ patients. Significantly elevated U6 or
U6/SNORD44 ratio was still observed in cancer-free
patients or patients with active metastasis compared
with healthy subjects (Table 7).
To determine whether differences in U6 levels retain
statistical significance in a larger cohort, we added sera
from 60 healthy subjects and 53 patients who are can-
cer-free to the above cohort and measured U6 and
SNORD44 levels. Characteristics of patients in this
extended cohort are presented in Additional file 2. U6
levels in patients with breast cancer were significantly
higher than those in healthy subjects (1.5-fold, P =
0.05) (Additional file 3). For unknown reasons,
SNORD44 levels in the sera of approximately 20% of
samples were undetectable. U6/SNORD44 ratio after
excluding SNORD44
- samples (Additional file 2)
remained significantly higher in patients with cancer
compared with healthy subjects (2.3-fold, P = 0.03)
(Additional file 3).
Analysis of sera from a third cohort of patients
To confirm the results, we analyzed sera from 12
healthy subjects and 18 patients with active metastasis
(cohort 3). U6 levels were elevated in sera of patients
with active metastasis but did not reach statistical signif-
icance, possibly due to the smaller sample size of
healthy subjects (Table 8). However, U6/SNORD44 ratio
was significantly elevated in sera of patients with active
metastasis compared with healthy subjects in this
cohort. In this cohort, as with the second cohort, we
observed significantly elevated miR-16 and miR-16/
SNORD44 ratio in patients with active metastasis. How-
ever, 5S and 5S/SNORD44 ratio in cohorts 2 and 3 were
incompatible with results from the first cohort. Overall,
our analysis included sera from 115 healthy subjects,
107 clinically disease-free women, and 33 women with
active metastasis. Taken together, these results reveal
reproducible upregulation of serum U6 levels in women
who experienced breast cancer, irrespective of disease
activity at the time of serum collection.
Discussion
This study was designed to address two critical issues
related to circulating miRNAs as a biomarker in breast
cancer: the first concerned normalization control and
the second was related to persistence of miRNA changes
in patients who are clinically cancer-free. Although ana-
lysis of candidate miRNAs did not reveal major cancer-
specific changes in serum profile, our results clearly
showed elevated levels of U6 RNA, which is often used
for normalization, in the sera of patients with breast
cancer. With SNORD44 as a normalization control, we
Figure 2 U6 and 5S levels in the sera after normalization with
microRNA 16 (miR-16) or small nucleolar RNA 44 (SNORD44).
Delta cycle threshold (CT) method (CT average of U6 or 5S minus
CT average of miR-16 or SNORD44) was used for this analysis; the
lower the delta CT, the higher the expression. The statistical
significance of differential expression and the fold change between
groups are presented in Table 4.
Table 5 Cancer subtype-specific differences in U6, 5S,
and other RNAs compared with healthy subjects
Small RNA ER
+/PR
+ cancer versus
healthy
ER
-/PR
- cancer versus
healthy
P value Fold change P value Fold change
U6 0.01 2.16 0.004 3.03
5S 0.087 1.52 0.02 2.1
miR-21 0.52 -1.09 0.79 1.05
miR-16 0.614 -1.11 0.962 1.01
SNORD44 0.21 1.09 0.29 1.09
U6-miR-16 0.02 2.4 0.02 3.00
U6-SNORD44 0.02 2.0 0.008 2.77
5S-miR-16 0.07 1.7 0.05 2.08
5S-SNORD44 0.196 1.4 0.055 1.92
miR-21-miR-16 0.96 1.01 0.91 1.03
miR-21-SNORD44 0.273 -1.19 0.85 -1.04
Small RNA levels in the serum of patients with estrogen receptor/
progesterone receptor-positive (ER/PR
+) or ER/PR
- cancer were compared with
those in the serum of healthy volunteers (experimental cohort). miR-16,
microRNA 16; miR-21, microRNA 21; SNORD44, small nucleolar RNA 44.
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both ER/PR
+ and ER/PR
- breast cancer patients who
were in remission. This also indicates that the type of
treatment has no effect on serum U6 levels as ER/PR
+
and ER/PR
- patients receive different therapies. Disease
activity did not appear to influence the levels of serum
U6 as sera from ER/PR
+ versus ER/PR
- or node-positive
versus node-negative patients did not show a statistically
significant difference in U6 levels. Sera of patients with
active disease also showed elevated levels of U6. Further
studies assessing U6 levels before and after treatment
are required to test the temporal effects of treatment on
serum U6 levels.
The above observations raise two important questions:
one is related to the source of serum U6 RNA and the
other is related to the mechanism(s) leading to altered
U6 levels in serum. It is generally believed that tumor
cells are the primary source of serum miRNAs [28].
Reduction of miR-92 in sera of patients with acute mye-
loid leukemia [19], reduction of 28 miRNAs in sera of
patients with lung cancer [18], and our observation of
elevated U6 RNA in sera of patients with metastasis-free
breast cancer favor the possibility that cancer alters the
release of miRNAs from distant organs or the immune
system. The majority of plasma microvesicles are derived
from leukocytes; therefore, cancer-induced alteration in
leukocyte functions may potentially contribute to miRNA
profile changes in the serum of patients with cancer [14].
Our observation of persistent change in U6 levels even
after a patient is cancer-free is slightly surprising. It is
possible that cancer-derived growth factors/cytokines,
stress, host response to cancer, or carcinogens result in
stable epigenetic changes in distant organs. In this con-
text, it was recently reported that chronic stress induces
epigenetic changes, which impact DNA methylation pat-
terns and consequent effects on gene expression in both
germline and somatic tissues [30]. Furthermore, neona-
tal experiences altering ERa levels in the adult mam-
mary gland and consequent effects on mammary tumor
incidence have been reported using animal models [31].
In addition, a recent study showed that individuals with a
persistent asymptomatic hepatitis B virus (HBV) infection
and patients with active HBV infection share a serum
miRNA profile, which is distinct from a healthy indivi-
dual [32]. Thus, a chronic infection/inflammatory condi-
tion may prompt certain organs to undergo permanent
change in gene expression pattern. An alternative possi-
bility, which may be provocative, is that upregulation of
serum U6 levels is a preamble to cancer initiation or sug-
gestive of a pre-cancerous state, similar to the creation of
a niche for metastasis by the vascular endothelial growth
factor receptor-1-positive (VEGFR-1
+) hematopoietic
Figure 3 Levels of U6 and 5S with or without normalization in the sera of patients who were diagnosed with estrogen receptor/
progesterone receptor-positive (ER/PR
+) or ER/PR
- tumors. The statistical significance of differential expression and the fold change between
groups are presented in Table 5.
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cells [33].
RNAP-III transcribes both U6 and 5S RNA [34,35].
Aberrant RNAP-III-mediated transcription during can-
cer progression is just beginning to be recognized.
RNAP-III upregulation is essential for cMyc-induced
transformation [36]. The major signaling pathways acti-
vated in cancer, including Ras, Raf, PI3K, and AKT,
enhance RNAP-III activity, whereas several tumor sup-
pressors, including retinoblastoma, PTEN, p53, and
BRCA1, decrease RNAP-III activity [35]. Inactivation of
BRCA1 alone is sufficient to increase U6 levels in cancer
cells [37]. Since we observed elevated U6 levels in the
sera of patients who are cancer-free at the time of sam-
ple collection as well as in the sera of patients with
metastasis, alteration in the RNAP-III transcription
machinery may be one of the systemic changes that
occur during cancer progression prior to diagnosis and
treatment. Recent serum protein biomarker profiling
studies have shown a ‘chronic inflammatory state’ in
patients with breast cancer [38]. Whether such an
inflammatory state alters serum U6 levels by modulating
RNAP-III activity is not known. Unlike RNA polymerase
II, RNAP-III has not been targeted for cancer therapy. It
is not known whether serum U6 influences the course
of the disease or whether blocking it will impact pro-
gression of the disease. It is also not known whether
serum U6 is complexed with Argonaute2 or HDL and is
delivered to heterotypic cells to modulate gene expres-
sion through alternative splicing [10,11]. We hope that
our observations will prompt additional studies using
inhibitors that can modulate (but not eliminate) the
activity of RNAP-III to control cancer cell growth or the
secondary effects of cancer or both.
Conclusions
This is the first study to report aberrant levels of U6
small RNA in sera of patients with breast cancer. Since
Figure 4 U6, U6/small nucleolar RNA 44 (SNORD44) ratio, 5S,
5S/SNORD44, microRNA 16 (miR-16), miR-16/SNORD44 ratio,
and SNORD44 levels in the serum of healthy subjects, patients
who are clinically cancer-free, and patients with active
metastasis. Ages at initial diagnosis and serum collection are
presented in Table 2. The statistical significance of differential
expression and the fold change between groups are presented in
Table 6.
Table 6 Comparison of expression levels of U6, 5S, and
other RNAs in the serum
Column ID P value Fold change
Metastasis versus healthy
U6 0.0005 4.31
U6-SNORD44 0.004 4.8
miR-16 0.001 3.4
miR-16-SNORD44 0.008 3.7
5S 0.0058 -23
5S-SNORD44 0.009 -21
SNORD44 0.708 -1.1
Cancer-free versus healthy
U6 3.68 × 10
-5 5.35
U6-SNORD44 0.00028 6.64
miR-16 0.0095 2.45
miR-16-SNORD44 0.015 3.04
5S 0.02 -11.0
5S-SNORD44 0.037 -9.0
SNORD44 0.39 -1.24
Metastasis versus cancer-free
U6 0.59 -1.24
U6-SNORD44 0.53 -1.39
miR-16 0.38 1.37
miR-16-SNORD44 0.67 1.23
5S 0.51 -2.06
5S-SNORD44 0.46 -2.38
SNORD44 0.68 1.12
Comparisons were made between healthy subjects and patients with
metastasis, healthy subjects and cancer-free patients, and patients with
metastasis and those who were cancer-free (cohort 2). miR-16, microRNA 16;
SNORD44, small nucleolar RNA 44.
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Page 8 of 10elevated U6 levels were observed in patients who are
clinically cancer-free, serum U6 levels may serve as a
‘surrogate marker’ for permanent, cancer-induced sys-
temic changes, irrespective of the disease course. Several
challenges lie ahead; these are related to identifying the
nature of these systemic changes as well as organs other
than the primary site of cancer. Distinguishing cancer-
associated deleterious systemic changes from insignifi-
cant changes is a huge challenge. Nonetheless,
additional studies in this direction may help us to
understand cancer as a systemic disease and potentially
to develop treatment strategies targeting the ‘organ
component’ and ‘systemic component’ of cancer.
Additional material
Additional file 1: A detailed description of procedure used for
serum collection.
Additional file 2: Characteristics of healthy and breast cancer
patients who are cancer free at the time of serum collection
(extended cohort 2).
Additional file 3: Levels of U6 without (left) and with normalization
to small nucleolar RNA 44 (SNORD44) (right) in the sera of healthy
volunteers and breast cancer patients who are cancer free at the
time of serum collection (extended cohort 2). U6 levels in the sera
without (left) or after normalization (right) with SNORD44 for the
extended cohort 2. Delta CT method (Ct average of U6 - Ct average of
SNORD44) was used for this analysis. Lower the delta CT, higher the
expression. Additional file 2 provides details of patient characteristics and
number of samples used for this analysis.
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